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235 Factors inﬂuencing the worsening of lung function between 16
and 18 years of age in Czech patients
D. Zemkova1, L. Smolikova1, L. Fila1, J. Bartosova1, M. Macek Jr.1, V. Vavrova1.
1CF Centre, University Hospital Prague Motol, Charles University – 2. Medical
School, Prague, Czech Republic
Despite improved medical care we still observe marked deterioration of lung
function between 16 and 18 years of age followed by increased mortality. The
aim of the study was to analyze the factors inﬂuencing such decline. We analyzed
lung function tests of 87 patients longitudinally followed up at our Centre between
14−18 years who were treated by modern approaches for at least 5 years. We
evaluated the inﬂuence of gender, CFTR genotype, pancreatic function, bacterial
infection, CFRD, nutritional status and previous development of their lung disease
on its deterioration between 16 and 18 years. FEV1 at the age of 16 years was
76.5±24.4%, at 18 years 65±23.3%, two year’s FEV1 decline was 11.6±14%
(median 10%). We did not prove the inﬂuence of gender, genotype, pancreatic
function, nutritional status, diabetes and Pseudomonas aeruginosa infection on
this decline. In 42 patients infected by Burkholderia cepacia complex (Bcc) the
worsening was more marked 15.1±12.9% (med 12.5%), than in the remaining
45 patients 8.2±14% (med 6%; all above of the predicted value; p = 0.019). A
more pronounced deterioration was observed in patients whose lung function was
better at the age of 16 years (r = −0.369; p = 0.001). This association is particularly
strong in Bcc infected patients. The deterioration between 16 and 18 years of age is
inﬂuenced mainly by Bcc infection, but it is present also in other patients. Finally,
we have to consider non-compliance with therapy, during the age of transition to
adulthood, as another deleterious factor.
Supported by: VZFNM00064203.
236 Listing patients to lung transplantation (LTx). Experience of
110 cases in the CF Center of Verona
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C. D’Orazio1, S. Volpi1. 1Cystic Fibrosis Center, Verona, Italy
In the period 1999–2008 110 pts were evaluated for LTx by a multidisciplinary
team (MD, physiotherapist, psychologist, social assistant). In 99% of cases the
main indication was respiratory insufﬁciency, in one recurrent severe haemoptysis.
3 patients were listed for double L and liver Tx, one for double L and kidney.
Psychiatric disorders in 1 case was considered an exclusion criteria but the pt
was eventually listed by the surgical LTx Center. Other exclusion criteria were M
cheloneae infection, thyroid or colon carcinoma. One of two patients with previous
lobectomy/pneumectomy was excluded for the presence of severe thoracic organ
displacement. B cepacia (genomovar III), HIV infection, multiresistant P aerug-
inosa, severe malnutrition, prolonged steroid treatment, young age, severe portal
hypertension with TIPS, mechanical ventilation were not considered exclusion
criteria. Pts were referred to 5 surgical centers. The median age was 26 yrs and 17
pts were <18 years. Thirty-three pts died in the waiting list (70% in the ﬁrst year)
and 62 were successfully transplanted (median time in list 7 months). Patients who
died early (<1 year) in list had required signiﬁcantly more iv antibiotic treatment
(93±43 vs 63±47 days) in the year before listing but did not differ otherwise
(diabetes, gender, age, BMI, pathogens) from those who survived >1 yr in the list.
Overall survival after Tx is 75% at 5 years.
Conclusion: criteria to exclude CF pts from LTx are very few, even conditions such
as HIV infection, B cenocepacia could be questioned as absolute contraindications.
Recognizing patients with very poor prognosis is a major challenge, but our more
recent experience lead us to consider patients for LTx earlier than ten years ago.
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“suboptimal organs”: insights from decision analysis
A. Thomas1, Y. Locke1, T.J. Locke2, M. Wildman1. 1Adult Cystic Fibrosis Unit,
Northern General Hospital, Shefﬁeld, United Kingdom; 2Cardiothoracic Unit,
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Background: Lung transplantation is an important treatment option for Cystic
Fibrosis (CF) patients with end stage lung disease. Organs are limited and many
patients die on the waiting list. One option for increasing organ availability is to
use organs that are suboptimal and have been optimised via an ex-vivo management
programme. Patients can ﬁnd it difﬁcult to decide whether to accept extended pool
organs. Patients accepting such organs may have a lower probability of dying on
the transplant list but a greater risk of dying after transplant. Decision analysis
(DA)is a technique that allows complex and uncertain decisions to be dealt with
systematically. The clinician provides expertise by identifying the possible outcomes
and their probability and a description of the health state associated with each
outcome. The patient provides expertise by placing a value on the outcomes
described. The decision tree then integrates the probabilities of the various outcomes
and the patients values for those outcomes in order to calculate an optimal decision.
Methods: We used a medline search to identify outcomes for conventional and
extended donor pool transplantation. We used clinical experience to describe the
resultant health states and imputed values for those states. We used Treeage software
to construct a decision tree and used the roll-back function to identify the optimal
decision.
Results: DA suggested that given the death rate on the waiting list in the UK CF
patients would probably choose to receive organs from an extended pool.
Discussion: Though patients may differ in the valuation of outcomes the tree allows
those values to be incorporated and the DA to be re-run.
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Objective: CF have marked loss of bone mass caused by malnutrition, lower sex
hormones, inactivity and chronic inﬂammation.
In literature the prevalence of osteoporosis is about 30% and compression fractures
is 7−35% in adult CF. But no osteologic data exist, when CF are exposed to a high
immunosuppressive and glucocorticoid therapy after lung transplantation (CFTX).
Methods and Results: We therefore retrospectively analysed clinical data, bone
radiographs and dual-energy X-ray absorptiometries (DXA) of 21 CF (9 m/12 f; age:
28±9 yrs), transplanted between 01/99 and 08/04. The mean follow up was 2 yrs
(range: 0.1−8.5 yrs). Only 1 CFTX (4.7%) had normal T-values, 3 CFTX (14.3%)
had osteopenia, 11 CFTX (52.4%) had osteoporosis and 6 CFTX (28.6%) had
vertebral fractures. 50% of vertebral fractures were diagnosed within the ﬁrst year
after lung transplantation. Bone mineral density was markedly decreased (lumbar
vertebral column-mean: 0.97 g/cm2; T score: −2.9 − femur mean: 0.73 g/cm2,
T score −2.64) and predictive for compression fractures. Parathyroid hormone
(PTH) was elevated in 82%, osteocalcin in 45% and 25-Hydroxyvitamin D was
low in 36%. The creatinine clearance in CFTX was 56.4ml/min in mean. Despite
of high physical activity and adequate osteoporosis therapy no signiﬁcant increase
of bone mass could be seen after CFTX.
Conclusions:
1. All adult CF should be screened for osteoporosis as early as possible.
2. A biphosponate/calcium/vitD therapy in CF with osteopenia or osteoporosis
before LuTX and after CFTX, in combination with physical activity and optimal
nutrition may reduce osteoporosis and vertebral column fractures within the ﬁrst
year after CFTX.
